StockData
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. (ANTX) company profile

ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$4.23−0.24 (-5.37%)

Close on Nov 17, 2026Market cap $159.62MP/E –Yield –

About AN2 Therapeutics

Pharmaceutical Preparations, SIC 2834

AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics using its proprietary boron chemistry platform. Its research and clinical development pipeline spans hematologic conditions, infectious diseases, and oncology. The company's lead clinical candidate, epetraborole, is being developed for adult patients with phlebotomy-dependent polycythemia vera and individuals suffering from Mycobacterium abscessus complex lung disease. Another clinical asset, AN2-502998, targets patients with chronic Chagas disease. In addition, AN2 conducts global health initiatives aimed at addressing severe bacterial infections, such as melioidosis and tuberculosis, in underserved populations worldwide.

The company operates without internal production facilities, relying on specialized third-party contract manufacturers for raw materials, active drug substances, and finished trial products. Its clinical research and development activities take place across clinical study sites located in the United States and India. AN2 Therapeutics maintains its principal executive offices and corporate headquarters in Menlo Park, California.

Summary of the business section of AN2 Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
AN2 Therapeutics, Inc.
Headquarters
Menlo Park, CA
Address
1300 El Camino Real, Suite 100 94025
Phone
(650) 331-9090
Employees
21, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
ANTX
Exchange
Nasdaq
IPO date
Mar 28, 2022
Shares outstanding
38M, Aug 6, 2026
Public float
$23.08M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1880438
CUSIP
037326105
ISIN
US0373261058
FIGI
BBG00QYLYBK4
Share class FIGI
BBG00QYLYBL3
EIN
82-0606654

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eric EasomChief Executive Officer, Director465,688
Joshua M. EizenSee Remarks207,546
Cameron C. Trenor IIIChief Medical Officer116,667
Sarah Joanne WilliamsPrincipal Accounting Officer66,311
Lucy DayChief Financial Officer118,363
Sanjay ChandaChief Development Officer118,823
Stephen David PriorChief Strategy Officer59,086
Kabeer AzizDirector439,113
Gilbert Lynn MarksDirector84,156
Patricia A. MartinDirector19,252
Robin Shane ReadnourDirector566,544
Margaret M. FitzPatrickDirector10,708
Joseph S. ZakrzewskiDirector145,538
Melvin K. SpigelmanDirector–
Stephanie WongDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Eric Easom
President, Chief Executive Officer and Board Chair
$603.75K$164.13K$275.54K$332.06K$7.50K$1.38M-17%
Josh Eizen
Chief Legal Officer and Chief Operating Officer
$450.00K$66.11K$110.98K$180.00K–$807.08K-24%
Lucy Day
Chief Financial Officer
$447.20K$52.55K$88.21K$178.88K$7.50K$774.34K-5%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 28, 2022
Offer price
$15.00
Securities offered
4,600,000
Gross proceeds
$69.00M
Exchange
Nasdaq
First trading day
Mar 25, 2022
First-day close
$15.40+2.7%
Lock-up ends (est.)
Sep 21, 2022

“Per Share Total Public offering price $ 15.00 $ 69,000,000 Underwriting discounts and commissions (1) $ 1.05 $ 4,830,000 Proceeds to AN2 Therapeutics, Inc., before expenses $ 13.95 $ 64,170,000 (1) See the section titled “Underwriting” for a description of the compensation payable to the underwriters.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 17, 2026, we had 21 full-time employees, consisting of research, manufacturing, clinical operations, quality, finance, and operational personnel.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?